XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents (Note 7) $ 3,369.0 $ 2,818.6
Short-term investments (Note 7) 149.4 109.1
Accounts receivable, net of allowances of $15.7 (2024) and $14.8 (2023) 10,294.8 9,090.5
Other receivables 1,756.9 2,245.7
Inventories (Note 6) 7,459.8 5,772.8
Prepaid expenses 8,250.6 5,540.8
Other current assets 134.6 149.5
Total current assets 31,415.1 25,727.0
Investments (Note 7) 3,200.2 3,052.2
Goodwill 5,768.4 4,939.7
Other intangibles, net 6,537.3 6,906.6
Deferred tax assets 7,392.3 5,477.3
Property and equipment, net of accumulated depreciation of $11,816.0 (2024) and $11,099.3 (2023) 16,171.8 12,913.6
Other noncurrent assets 5,121.8 4,989.9
Total assets 75,606.9 64,006.3
Current Liabilities    
Short-term borrowings and current maturities of long-term debt 2,074.3 6,904.5
Accounts payable 2,886.5 2,598.8
Employee compensation 1,703.3 1,650.4
Sales rebates and discounts 12,429.7 11,689.0
Dividends payable 0.0 1,169.2
Other current liabilities 5,580.3 3,281.3
Total current liabilities 24,674.1 27,293.2
Noncurrent Liabilities    
Long-term debt 29,045.4 18,320.8
Accrued retirement benefits (Note 9) 1,448.5 1,438.8
Long-term income taxes payable 3,878.8 3,849.2
Other noncurrent liabilities 2,239.4 2,240.6
Total noncurrent liabilities 36,612.1 25,849.4
Commitments and Contingencies (Note 10)
Eli Lilly and Company Shareholders' Equity    
Common stock 593.9 593.6
Additional paid-in capital 7,339.6 7,250.4
Retained earnings 13,627.2 10,312.3
Employee benefit trust (3,013.2) (3,013.2)
Accumulated other comprehensive loss (Note 11) (4,274.8) (4,327.0)
Cost of common stock in treasury (32.7) (44.2)
Total Eli Lilly and Company shareholders' equity 14,240.0 10,771.9
Noncontrolling interests 80.7 91.8
Total equity 14,320.7 10,863.7
Total liabilities and equity $ 75,606.9 $ 64,006.3